摘要
目的:系统评价镇肝熄风汤联合降压药治疗原发性高血压病的疗效和安全性。方法:通过检索PubMed数据库、维普数据库、中国知网、万方数据库、中国生物医学文献数据库等自建库至2020年8月收录的关于镇肝熄风汤联合降压药治疗原发性高血压病的随机对照试验,由2位研究者根据纳入及排除标准筛选文献、提取资料,使用RevMan 5.3软件进行Meta分析。结果:共纳入17项随机对照试验,2136例患者(治疗组1079例,对照组1057例),Meta分析结果显示:镇肝熄风汤联合降压药在降低收缩压(MD=-12.14,95%CI[-15.29,-8.99],P<0.01)和舒张压(MD=-7.16,95%CI[-9.06,-5.26],P<0.01),改善临床疗效(RR=1.18,95%CI[1.33,1.23],P<0.01),降低中医症状积分(MD=-6.51,95%CI[-7.55,-5.48],P<0.01),降低血脂(MD=-0.29,95%CI[-0.50,-0.07],P<0.05),降低不良反应发生率(MD=0.29,95%CI[0.16,0.53],P<0.01)等方面的作用优于对照组。结论:镇肝熄风汤联合降压药在降低收缩压、舒张压,改善临床疗效,降低中医症状积分,降低血脂方面疗效更为显著,安全性较好。
Objective:To systematically evaluate the efficacy and safety of Zhengan Xifeng Decoction combined with antihypertensive drugs in the treatment of primary hypertension.Methods:PubMed,VIP,CNKI,Wanfang Data,and CBM were searched for the randomized controlled trials(RCTs)of primary hypertension treated with Zhengan Xifeng Decoction combined with antihypertensive drugs from database inception to August 2020.The papers were screened out and information was extracted by two investigators according to the inclusion and exclusion criteria.RevMan 5.3 was used for Meta-analysis.Results:Seventeen RCTs were included,involving 2136 patients(1079 in the treatment group and 1057 in the control group).Meta-analysis results showed that Zhengan Xifeng Decoction combined with antihypertensive drugs could reduce systolic blood pressure(MD=-12.14,95%CI[-15.29,-8.99],P<0.01)and diastolic blood pressure(MD=-7.16,95%CI[-9.06,-5.26],P<0.01),improved clinical efficacy(RR=1.18,95%CI)[1.33,1.23],P<0.01),reduced TCM symptom scores(MD=-6.51,95%CI[-7.55,-5.48],P<0.01),decreased blood lipids(MD=-0.29,95%CI[-0.50,-0.07],P<0.05),and reduced the incidence of adverse reactions(MD=0.29,95%CI[0.16,0.53],P<0.01).Additionally,the effect was superior to that in the control group.Conclusion:Zhengan Xifeng Decoction combined with antihypertensive drugs is effective in reducing systolic and diastolic blood pressure,improving clinical efficacy,and decreasing TCM symptom scores and blood lipids,with good safety.However,the quality and quantity of the included papers are insufficient.Therefore,the results of the present study need to be confirmed by more high-quality research,and the safety also needs to be further verified.
作者
刘芬芬
周亚博
沈童
路永坤
杨俊红
Liu Fenfen;Zhou Yabo;Shen Tong;Lu Yongkun;Yang Junhong(Henan University of Chinese Medicine,Zhengzhou 450000;First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2022年第6期168-174,共7页
Pharmacology and Clinics of Chinese Materia Medica
基金
全国中医药创新骨干人才培训资助项目(编号:国中医药人教函[2019]128号)。
关键词
镇肝熄风汤
原发性高血压
系统评价
随机对照试验
安全性
Zhengan Xifeng Decoction(镇肝熄风汤)
primary hypertension
systematic review
randomized controlled trial
safety
作者简介
通信作者:杨俊红,主任医师,教授,硕士生导师,研究方向为中医药防治脑血管疾病,E-mail:13838119371@163.com;刘芬芬,硕士,研究方向为中医药防治脑血管疾病,E-mail:13253691968@163.com。
